期刊
CANCERS
卷 11, 期 3, 页码 -出版社
MDPI
DOI: 10.3390/cancers11030275
关键词
anaplastic lymphoma kinase; ALK; tyrosine kinase; dependence receptor; proapoptotic peptides; tyrosine kinase inhibitor; anaplastic large cell lymphoma; non-small-cell lung cancer; neuroblastoma; targeted therapy
类别
资金
- INSERM
- University of Toulouse III Paul Sabatier
- Fondation de France [R07055BB]
ALK is a receptor tyrosine kinase, associated with many tumor types as diverse as anaplastic large cell lymphomas, inflammatory myofibroblastic tumors, breast and renal cell carcinomas, non-small cell lung cancer, neuroblastomas, and more. This makes ALK an attractive target for cancer therapy. Since ALK-driven tumors are dependent for their proliferation on the constitutively activated ALK kinase, a number of tyrosine kinase inhibitors have been developed to block tumor growth. While some inhibitors are under investigation in clinical trials, others are now approved for treatment, notably in ALK-positive lung cancer. Their efficacy is remarkable, however limited in time, as the tumors escape and become resistant to the treatment through different mechanisms. Hence, there is a pressing need to target ALK-dependent tumors by other therapeutic strategies, and possibly use them in combination with kinase inhibitors. In this review we will focus on the therapeutic potential of proapoptotic ALK-derived peptides based on the dependence receptor properties of ALK. We will also try to make a non-exhaustive list of several alternative treatments targeting ALK-dependent and independent signaling pathways.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据